ATA Guidelines Tools

Thyroid Disease in Preconception, Pregnancy, and Postpartum

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/1545288

Contents of this Issue

Navigation

Page 15 of 53

Thyroid Dysfunction and Infertility 16 Recommendations Table 5. Overt Hypothyroidism in Women With Infertility Strength * Level # In women with newly diagnosed or uncontrolled overt hypothyroidism, fertility treatment should be delayed until euthyroidism is restored. Good Practice Statement Women with overt hypothyroidism who are planning pregnancy should be treated with levothyroxine (LT4 ). Strong Moderate yroid preparations other than levothyroxine (LT4 ), such as liothyronine (LT3) or desiccated thyroid extract, should not be used in women planning pregnancy. Strong Low * Strength of Recommendation; # Level of Evidence; Good Practice Statement. Recommendations Table 6. Subclinical Hypothyroidism in Women With Infertility Strength * Level # In women with newly diagnosed or uncontrolled subclinical hypothyroidism, fertility treatment may be delayed until the spontaneous restoration or therapy-induced restoration of euthyroidism. Conditional Low Subclinical hypothyroidism with a TSH >10 mU/L should be treated with levothyroxine. Good Practice Statement For all women with newly diagnosed subclinical hypothyroidism, diagnostic confirmation with rechecking TSH and FT4 may be done in 4–6 weeks. If the TSH concentration normalizes upon repeat measurement: 1. TPOAb negative women do not require biochemical follow-up and may be advised to seek medical evaluation upon the development of hypothyroid symptoms. 2. TPOAb positive women may be followed-up with TSH testing every 3–6 months when planning pregnancy, and once pregnant, every 4–6 weeks during the first half of pregnancy, at least once in the third trimester, and 4–6 weeks after any dose adjustment. If subclinical hypothyroidism is persistent upon repeat testing : 1. Low dose (25–75 mcg/day) levothyroxine may be started, with a TSH measurement aer 4–6 weeks and levothyroxine dose titrated to a target TSH between 0.5–2.5 mU/L. Conditional Moderate Conditional Low * Strength of Recommendation; # Level of Evidence; Good Practice Statement.

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Thyroid Disease in Preconception, Pregnancy, and Postpartum